Immune checkpoint inhibitors (ICIs), which primarily comprise programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors, have become the standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) without driver gene mutations. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.